Weaker immune response against COVID-19 may be attributed to the more targeted immunosuppressive mechanism of biologic DMARDs. Rheumatoid arthritis (RA) patients receiving biologic disease-modifying ...

Treatment with biologic DMARDs vs standard therapy improved clinical response rates and flare outcomes among patients with polyarticular JIA.

Biologic vs conventional DMARDs may offer cardioprotective benefits among patients with PsA, though an increased risk for infection requires vigilance.

A study looked at more than 23,600 Medicare beneficiaries with RA who had received a ≥30-day prescription of an opioid drug. Participants were grouped according to those who had been prescribed a ...

Please provide your email address to receive an email when new articles are posted on . Nearly all bDMARDs and tsDMARDs feature infection or malignancy warnings from the FDA or European Medicines ...

SaveHealth reports on common rheumatoid arthritis medications, highlighting their effectiveness, side effects, and cost ...

Worries have persisted that cancer survivors in remission might face increased recurrence risk when treated with biologic drugs for autoimmune disease. This Danish study of rheumatoid arthritis ...

ROME — Daily baricitinib, an oral Janus kinase (JAK)1/2 inhibitor, produces rapid clinical improvement in the signs and symptoms of rheumatoid arthritis in patients with active disease who have failed ...

Traditional medications are synthesized through chemical reactions, whereas biologics are derived from and reproduced, at least partially, from living organisms. For instance, blood and plasma ...